User login
Inflammatory Bowel Disease Highlights From Digestive Disease Week 2024
Highlights in ulcerative colitis (UC) and Crohn's disease (CD) from Digestive Disease Week® (DDW) 2024 are reported on by Dr. Andres Yarur from Cedars Sinai Medical Center in Los Angeles.
Dr. Yarur opens by discussing two phase 3 studies focused on risankizumab (RZB), which is currently approved for treatment of CD and has shown efficacy in UC. The first showed an induction period extended from 12 to 24 weeks resulted in clinical response in more than half of patients with UC.
The second study compared maintenance therapy with RZB to ustekinumab in patients with CD and found that RZB resulted in a higher rate of remission.
Dr. Yarur next looks at a study that explored use of darvadstrocel, an allogeneic stem cell therapy, in a subset of patients with CD and complex perianal fistulas. The disappointing results of the ADMIRE-CD II trial showed no benefit over placebo.
Patients hospitalized with UC, a population with few therapeutic options, were the focus of the next study. The TRIUMPH study explored use of the Janus kinase inhibitor tofacitinib for these patients and found that clinical response was achieved by 58.3% of them by day 7.
The final study addressed a clinical challenge: devising the optimal vaccination strategy for patients on immunosuppressive or anti–tumor necrosis factor therapies. Dr. Yarur reports that the study found an intensified pneumococcal vaccine regimen was more immunogenic and provided immunity for a longer duration than did the standard regimen.
--
Andres J. Yarur, MD, Associate Professor of Medicine, Cedars Sinai Medical Center, Los Angeles, California
Andres J. Yarur, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Takeda; Pfizer; Arena; AbbVie; Bristol Myers Squibb; Boehringer Ingelheim; Celltrion
Highlights in ulcerative colitis (UC) and Crohn's disease (CD) from Digestive Disease Week® (DDW) 2024 are reported on by Dr. Andres Yarur from Cedars Sinai Medical Center in Los Angeles.
Dr. Yarur opens by discussing two phase 3 studies focused on risankizumab (RZB), which is currently approved for treatment of CD and has shown efficacy in UC. The first showed an induction period extended from 12 to 24 weeks resulted in clinical response in more than half of patients with UC.
The second study compared maintenance therapy with RZB to ustekinumab in patients with CD and found that RZB resulted in a higher rate of remission.
Dr. Yarur next looks at a study that explored use of darvadstrocel, an allogeneic stem cell therapy, in a subset of patients with CD and complex perianal fistulas. The disappointing results of the ADMIRE-CD II trial showed no benefit over placebo.
Patients hospitalized with UC, a population with few therapeutic options, were the focus of the next study. The TRIUMPH study explored use of the Janus kinase inhibitor tofacitinib for these patients and found that clinical response was achieved by 58.3% of them by day 7.
The final study addressed a clinical challenge: devising the optimal vaccination strategy for patients on immunosuppressive or anti–tumor necrosis factor therapies. Dr. Yarur reports that the study found an intensified pneumococcal vaccine regimen was more immunogenic and provided immunity for a longer duration than did the standard regimen.
--
Andres J. Yarur, MD, Associate Professor of Medicine, Cedars Sinai Medical Center, Los Angeles, California
Andres J. Yarur, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Takeda; Pfizer; Arena; AbbVie; Bristol Myers Squibb; Boehringer Ingelheim; Celltrion
Highlights in ulcerative colitis (UC) and Crohn's disease (CD) from Digestive Disease Week® (DDW) 2024 are reported on by Dr. Andres Yarur from Cedars Sinai Medical Center in Los Angeles.
Dr. Yarur opens by discussing two phase 3 studies focused on risankizumab (RZB), which is currently approved for treatment of CD and has shown efficacy in UC. The first showed an induction period extended from 12 to 24 weeks resulted in clinical response in more than half of patients with UC.
The second study compared maintenance therapy with RZB to ustekinumab in patients with CD and found that RZB resulted in a higher rate of remission.
Dr. Yarur next looks at a study that explored use of darvadstrocel, an allogeneic stem cell therapy, in a subset of patients with CD and complex perianal fistulas. The disappointing results of the ADMIRE-CD II trial showed no benefit over placebo.
Patients hospitalized with UC, a population with few therapeutic options, were the focus of the next study. The TRIUMPH study explored use of the Janus kinase inhibitor tofacitinib for these patients and found that clinical response was achieved by 58.3% of them by day 7.
The final study addressed a clinical challenge: devising the optimal vaccination strategy for patients on immunosuppressive or anti–tumor necrosis factor therapies. Dr. Yarur reports that the study found an intensified pneumococcal vaccine regimen was more immunogenic and provided immunity for a longer duration than did the standard regimen.
--
Andres J. Yarur, MD, Associate Professor of Medicine, Cedars Sinai Medical Center, Los Angeles, California
Andres J. Yarur, MD, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Takeda; Pfizer; Arena; AbbVie; Bristol Myers Squibb; Boehringer Ingelheim; Celltrion
